Envista
QUAKERTOWN, PA / ACCESSWIRE / May 16, 2024 / Today, DEXIS launches the latest innovation in its digital ecosystem with an all-new dental intraoral sensor, the DEXIS™ Ti2 Sensor. The DEXIS digital ecosystem is a comprehensive, AI-powered platform for dental imaging, designed to connect and streamline digital workflows for enhanced productivity.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.DEXIS Ti2 Sensor
The Ti2 sensor builds on the success of its predecessor, the DEXIS™ Titanium Sensor, the #1 digital intraoral sensor in the United States.* In 2023, DEXIS sensors processed over 167 million images, making it a top choice for intraoral sensors and scanners, as well as x-ray and CBCT technology worldwide.
Bringing several new features to the DEXIS 2D imaging portfolio, the Ti2 sensor includes:
- A housing design that's twice as durable as previous generations
- A proactive servicing module
- Access to 2D AI Dental Findings that automatically detect up to six types of dental findings on 2D radiographs
With DEXIS, 2D AI Dental Findings are integrated into both DTX Studio™ Clinic and DEXIS Imaging Suite software-not a separate third-party application. 2D AI Dental Findings automatically identifies periapical radiolucency, bone loss, calculus, caries, discrepancy at margin of existing restoration, and root canal filling deficiency.
"For patients with periodontal disease, we have identified sub-gingival calculus and monitored their bone levels. Caries detection and diagnosis is clear and precise with the contrast available with these images," said Dr. Moe Katz of Katz & Pfeffer Dental Studio.
The Ti2 sensor housing is twice as durable and two times as drop-resistant as the Titanium Sensor. The new posterior holder and WiseAngle™ cable design reduce stress on the sensor/cable connection, further strengthening the Ti2 sensor.
DEXIS also focuses on maximizing the productivity of the dental practice with the newly launched DEXIS Connect Pro. The solution proactively monitors the health of the DEXIS family of sensors through IoT technology and automatically arranges support or equipment replacements if performance issues are ever detected.
"DEXIS Connect Pro provides the kind of customer experience I've come to expect from DEXIS," says Amber Metro-Sanchez, dental hygienist at Omni Dental. "The knowledge that my sensor communicates with DEXIS support and that they're ready to help me if I ever need it gives me peace of mind. They've always been so responsive and helpful, DEXIS Connect Pro demonstrates the kind of attention to customer care and continuous innovation I've grown accustomed to with DEXIS."
Through the use of CleanCapture™ technology, the Ti2 sensor captures high-resolution images by reducing noise and enhancing anatomical detail. The technology allows the sensor to be flexible and ready to adapt to varying exposure levels, generator usage, or positioning techniques to capture clear, accurate images reliably - even in challenging circumstances.
Equipped with its PerfectSize™ design, the Ti2 sensor is engineered to fit every patient comfortably, making it a convenient, one-size-fits-all solution for busy practices.
Experience the new DEXIS Ti2 Sensor at booth 1665 at CDA South on May 16-18, 2024.
*DEXIS Titanium Sensor- December 2023 SDM US Market Share Data.
About DEXIS
DEXIS has been a global leading brand in digital radiography for 70+ years. Today, DEXIS has brought together the most trusted brands in 3D imaging, intraoral scanning solutions, and diagnostic software to provide patients with a complete digital diagnostic solution under a brand name. Our innovative award-winning technology enhances how the patient is diagnosed, accelerates the workflow, and delivers simple treatment paths with better patient outcomes. For more information, please visit https://www.dexis.com.
Contact Information:
Hayley Reed
Regional Marketing Director, DEXIS IOS
hayley.reed@envistaco.com
(714) 628-8533
SOURCE: DEXIS
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
Accurate Background Partnering with Konfir to Provide Fast, Secure Instant Employment Verification in the United Kingdom5.12.2024 09:15:00 CET | Press release
IRVINE, CA / ACCESSWIRE / December 5, 2024 / Accurate Background, headquartered in Irvine, CA, and the largest privately held and minority-owned global provider of compliant background checks, drug and health screening, and workforce monitoring solutions, has announced a new partnership with Konfir, an innovative company providing employment verification technology in the UK. This collaboration will provide Accurate's clients access to Konfir's real-time verification tools via Accurate technology. Accurate's integration of Konfir's instant employment verification API will allow candidates to aggregate real-time data from multiple data sources including Payroll, HMRC, and Open Banking, streamlining screening processes and reducing time-to-hire. In addition, Accurate will now offer enhanced fraud mitigation tools through Konfir's suite of insights helping employers identify potential hiring risks more effectively. Kevin Stone, Sales & Marketing Director at Accurate, commented: "At Accura
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 20245.12.2024 09:10:00 CET | Press release
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET. For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof. Dr. med. Director of Department, Department of Neurology, Universitatsspital, Zur
Atha Energy Identifies Numerous Outcrops Hosting High-Grade Uranium Mineralization5.12.2024 07:00:00 CET | Press release
HIGHLIGHTS Surficial mapping was conducted as part of the 2024 Angilak Exploration Program that focused on areas strictly proximal to the Lac 50 Deposit and achieved its objective of discovering high-grade uranium mineralization on surface beyond the extents of the Lac 50 Deposit's Exploration Target Model; High-grade surficial uranium mineralization was identified between Lac 48, Lac 50, Lac 52, and Lac 54 trends, collectively known as the Lac 50 Deposit, along prospective new parallel trends; Discovery of outlined outcrops containing high-grade uranium mineralization along strike from the Lac 50 Deposit provide basis for future exploration and significantly de-risk expansion efforts; A zone of extensive bedrock outcrop with radioactivity up to >60,000 counts per second (cps) - >10,000 cps is indicative of high-grade uranium mineralization - was identified over a 3-kilometre strike length. The new discovery is located between the Mushroom Lake zone on the Lac 52 trend and the Hot zone
TACACS.net: Strengthening Network Security with Native Active Directory Integration4.12.2024 16:55:00 CET | Press release
The Weakest Link in Cybersecurity: Addressing Authentication Vulnerabilities SAN JOSE, CA / ACCESSWIRE / December 4, 2024 / In an era where 75% of security breaches are attributed to weak authentication, the importance of robust cybersecurity measures has never been greater. Recognizing this critical need, TACACS.net has emerged as the #1 choice for Active Directory (AD) integration, offering unmatched reliability, performance, and security. Authentication is often the weakest link in network security. If a hacker cannot authenticate to a device, they cannot exploit it. TACACS.net addresses this vulnerability by delivering a solution built to meet the needs of modern organizations, ensuring fast, secure, and seamless integration with existing infrastructure. Why TACACS.net Stands Out Most organizations rely on Active Directory to manage users, but competing solutions depend on middleware-complex intermediaries that often fail, usually at the worst possible time. TACACS.net is the only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom